Stratos Product Development Provides Design Expertise on AcelRx Pharmaceuticals' Advanced Drug Delivery System for Acute Pain...
01 December 2011 - 5:00AM
Marketwired
Stratos Product Development LLC today announced its President, Sean
MacLeod, and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) Chief
Executive Officer, Richard King, will present at the BIOMEDevice
conference in San Jose on Stratos' continued collaboration with
AcelRx to support software and electrical design of AcelRx's lead
product candidate, ARX-01.
ARX-01 is an advanced drug delivery system for patient
controlled analgesia (PCA) and is expected to enter Phase 3
clinical trials in late 2011 or early 2012. Stratos' services on
the ARX-01 project included embedded software design, electrical
engineering, human factors support, project management and quality
engineering with Stratos ISO 13485 compliant design controls. The
presentation -- Innovation on Demand: When Customer Insight Meets
Technical Creativity -- will take place on December 6, 2011 at
12:00 p.m. at the San Jose McEnery Convention Center.
AcelRx's ARX-01 sublingual PCA system was developed to address
challenges in managing post-operative pain and is a non-invasive,
sublingual alternative to intravenous patient-controlled analgesia
(IV PCA). Acute pain management in the hospital, in particular
post-operative analgesia, remains a challenge for healthcare
providers. There are many deficiencies associated with the current
use of IV PCA that can negatively impact patient safety, well-being
and recovery.
"Stratos has been a true extension of the AcelRx internal
engineering team in the development of ARX-01. Their expertise in
software and electrical design has complemented AcelRx' mechanical
engineering capabilities to produce a dispensing system that meets
the needs of patients, healthcare providers and payers alike,"
Richard King, President and CEO of AcelRx, said.
"Working with AcelRx presented an ideal opportunity for Stratos
to be a successful innovation partner," Sean MacLeod, President,
Stratos Product Development, said. "Stratos' consultative approach,
multi-discipline understanding of product development and the
complementary cultures of the two companies allowed us to provide
optimal ideas and solutions. We look forward to seeing the final
product in the marketplace."
Read the case study.
About Stratos Product Development At
Stratos, we know a cohesive, experienced team of developers can't
be built overnight. For 25 years, we've been building a superior
ecosystem for innovative product development. Expert industrial
designers, researchers, software developers, electrical,
mechanical, manufacturing and quality engineers and professional
project managers are here to support your next product development
challenge. Our collaborative, cross-discipline approach enables us
to reduce time-to-market, maximize product opportunities and create
compelling product solutions for users and unmet needs in the
marketplace. We partner with clients worldwide, from start-up
companies to Fortune 500 corporations.
About AcelRx Pharmaceuticals Based in
Redwood City, CA, AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) is a
specialty pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain. AcelRx's lead product candidate, the
ARX-01 Sufentanil NanoTab PCA System, which is in preparation for
Phase 3 clinical development, is designed to solve the problems
associated with post-operative intravenous patient-controlled
analgesia which has been shown to cause harm to patients following
surgery because of the side effects of morphine, the invasive IV
route of delivery and the inherent potential for programming and
delivery errors associated with the complexity of infusion pumps.
AcelRx has two additional product candidates which have completed
Phase 2 clinical development: ARX-02 for the treatment of cancer
breakthrough pain, and ARX-03 for providing mild sedation, anxiety
reduction and pain relief for patients undergoing painful
procedures in a physician's office. A fourth product candidate,
ARX-04, is a sufentanil product for the treatment of
moderate-to-severe acute pain that is expected to enter Phase 2
clinical development in the fourth quarter of 2011 under a grant
from the U.S. Army Medical Research and Material Command, or
USAMRMC.
Add to Digg Bookmark with del.icio.us Add to Newsvine
MEDIA CONTACT: Rebecca Dawson Director, Marketing
Communications Email Contact (206) 448-1388 www.stratos.com
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Oct 2023 to Oct 2024